<DOC>
	<DOC>NCT00803374</DOC>
	<brief_summary>The purpose of this study is to determine if BMS-663513 administered in combination with ipilimumab to patients with advanced malignant melanoma is safe and tolerable</brief_summary>
	<brief_title>Combination of Anti-CD137 &amp; Ipilimumab in Patients With Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Histologically or cytologically confirmed malignant melanoma Stage III (unresectable) or Stage IV disease which may have been treated with up to one prior cytotoxic chemotherapy and/or up to 3 other therapeutic regimens Willing to undergo up to 3 biopsies of an accessible lesion Active/symptomatic brain metastases Primary ocular melanoma or primary tumor of unknown origin Concurrent autoimmune disease Previous treatment with a CD137 agonist or CTLA4 inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>